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Endometrial cancer (EC) is the most frequent gynecological malignancy in developed countries, and
accounts for 6e9% of female malignancies. The prevalence is growing in overweight individuals and
those with medical comorbidities such as diabetes and hypertension. Nodal status is a key determinant
of the outcome and there is a strong rationale incorporating sentinel lymph node (SLN) biopsy in the
management of EC. We performed a systemic review concerning studies investigating the role of lapa-
roscopic detection of SLN in early-stage EC. The detection rate and sensitivity of the laparoscopic
approach in SLN ranged from 69.6% to 100% and 58.6% to 100%, respectively. The combination of dye and
radiocolloid detection substances is the best method for SLN detection in EC. The use of pericervical
injection and the laparoscopic approach increase the detection rate of SLNs, especially in the iliac lymph
node groups. The hysteroscopy injection technique highlights the presence of isolated para-aortic lymph
node metastasis. However, the precise method of SLN biopsy in EC needs to be determined further.
Copyright  2013, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Endometrial cancer (EC) is the most frequent gynecological
malignancy in the developed world and its incidence is increasing.
Histological grade, depth of myometrial invasion, and lymph node
status are the main prognostic factors in EC. Despite the increasing
frequency of this disease, the treatment of this cancer in its early
stage remains controversial, especially the role of comprehensive
surgical staging, which includes pelvic and para-aortic lymphade-
nectomy for all patients. The proportion of womenwho have pelvic
or para-aortic lymph node involvement in Stage I disease ranges
from 4.7% to 13% or 0% to 3%, respectively, whereas in Stage II
disease, the proportion of women with pelvic lymph node
involvement ranges from 18.8% to 44.8%.1e5
In the recent revised 2009 International Federation of Gyne-
cology and Obstetrics (FIGO) staging system, the major changesnd Gynecology, Chang Gung
g Gung University, College of
, Taiwan.
uang).
ia-PaciﬁcAssociation forGynecologicEninvolved systemic pelvic and/or para-aortic lymphadenectomy, for
example, Stage IIIC1 indicating positive pelvic nodes and Stage IIIC2
indicating positive para-aortic nodes.6 However, complete systemic
pelvic and para-aortic lymphadenectomy may produce additional
morbidity that may not result in additional survival outcome
beneﬁt, and the possibility of overtreatment in clinically early stage
EC. The challenge is to identify a surgical technique that provides
accurate staging information about nodal status while avoiding the
potential of overtreatment in low-risk groups and undertreatment
in patients with metastatic disease. This can avoid the potential
unnecessary morbidity associated with systemic lymphadenec-
tomy, such as lymphedema, lymphocyst formation, and prolonged
operative time.
The well-established concept of sentinel lymph node (SLN)
sampling for malignancies is accepted for melanoma and breast
and vulva cancer.7e10 Based on the orderly, sequential ﬂow of
lymphatic ﬂuid from the site of primary tumor to the lymphatic
vessels, SLNs or lymphatic mapping is increasing in popularity
among gynecological oncologists. In the era of minimally invasive
surgery, a combination of laparoscopic hysterectomy and SLN bi-
opsy provides an appealing alternative apart from traditionaldoscopyandMinimally InvasiveTherapy.PublishedbyElsevierTaiwanLLC.All rights reserved.
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tion and detection rate in early stage EC without compromising the
diagnostic accuracy, as well as several other advantages of laparo-
scopic surgery.
Based on these considerations, we conducted a systematic re-
view of the evidence regarding the efﬁcacy of the laparoscopic
approach for SLN biopsy in EC.
Methodology
Data sources and study selection
A comprehensive, systematic computer literature search for
published English-language studies in humans was conducted us-
ing PubMed up to February 2012. The following keywords were
used: “laparoscopic”, “sentinel node” and “endometrial or endo-
metrium or uterine cancer/carcinoma”. The list of articles was
supplemented by extensive crosschecking of reference lists of the
identiﬁed articles. Review articles, letters, comments, meeting ab-
stracts, unpublished data, and case reports were excluded. Inclu-
sion criteria were: (1) laparoscopic approach in detecting sentinel
nodes with a minimal sample size of >10 participants, and publi-
cations that provided identiﬁcation of effectiveness and diagnostic
performance of SLN detection techniques; (2) studies that used
radiolabeled tracers and/or blue dye in the sentinel node proce-
dure; and (3) studies that involved only early stage EC.
Data extraction
We recorded data from each of the selected studies. The
following data were extracted: (1) authors and year of publication;
(2) sample size; (3) tracers and methods used for SLN procedures;
(4) number of SLNs resected per study; (5) detection rate and
sensitivity of SLNs for each study; and (6) exact location of SLNs
detected in each study. A positive SLN is a positive node that is
identiﬁed with or without ultrastaging (serial sections or
immunohistochemistry).
The detection rates were calculated as the number of patients
with at least one detected pelvic or para-aortic SLN, divided by the
total number of patients who underwent labeling and SLN map-
ping. Sensitivity was estimated as the proportion of true positives
(patients with positive pelvic or para-aortic SLNs) among the pa-
tients with positive pelvic or para-aortic lymph nodes. NegativeTable 1
Characteristics of studies reviewed.
Authors Year n FIGO stage Tracer used Injection site
Pelosi et al16 2002 16 Ib Tc99m þ PB Cervical
Gargiulo et al18 2003 11 IbeIIa Tc99m þ PB Cervical
Holub et al17 2004 25 I PB Cervical
Barranger et al28 2004 17 IaeII Tc99m þ PB Cervical
Delpech et al29 2007 23 IaeII Tc99m þ PB Cervical
Ballaster et al20 2008 38 IaeII Tc99m þ PB Cervical
Perrone et al22 2008 40 e Tc99m Cervical (23)
Hysteroscopy (17)
Barranger et al21 2009 33 IeII Tc99m þ PB Cervical
Ballester et al12 2011 125 IeII Tc99m þ PB Cervical
FIGO ¼ International Federation of Gynaecology and Obstetrics; H/E ¼ hematoxylin an
Tc99m ¼ Technetium 99m.predictive value was found by dividing the number of true nega-
tives (patients with negative pelvic SLNs) by the number of all
patients without pelvic lymph nodes metastasis.
Results
Up to February 2012, the initial search retrieved nine out of 29
articles from Pubmed. After screening, only nine articles concern-
ing laparoscopic detection of SLNs in EC fulﬁlled the inclusion
criteria. An overview of the results from the studies included in the
analysis is presented in Tables 1e3.
A total of 328 patients were included in the nine reviewed
studies, with a mean number of 36.56  11.56 patients per study
(median: 25 patients, range: 11e125 patients). In 311 out of 328
patients, reagent tracers were injected into the pericervical region,
whereas 17 patients received hysteroscopy-guided injection. Seven
studies used dual labeling tracers (patent blue plus radiolabeled
colloid) and two studies used a single reagent tracer. Those using
radiolabeled colloid had preoperative lymphoscintigraphy per-
formed 1 day prior to the operation and intraoperative endoscope
gamma probing for SLN mapping (Table 1).
The SLN detection rates varied from 69.6% to 100% for pericer-
vical injection (mean: 87.66  3.05) and 64.7% for hysteroscopy-
guided injection. The low SLN detection rate of 64.7% was
observed in the study by Perrone et al; probably due to the large
number of detection failures in early cases due to the learning
curve. The use of pericervical injection, mostly at four different
sites, correlated with the increasing detection rate.
The range of SLN sensitivity and NPVwere 58.8e100% and 10.5e
100%, respectively (Table 2). The mean number of SLNs removed
was 47.89  8.77. The mean pooled bilaterality of SLNs was
50.80  5.29%.
The most common site of SLNs was the iliac region, with 50e
100% of the total. SLNs were detected in the para-aortic region by
Barranger et al (2.5%) and Perrone et al (18.2%). The superiority of
hysteroscopy-guided injection over pericervical injection for
detection of isolated para-aortic SLNs in patients with EC was
demonstrated by Perrone et al (Table 3).
Discussion
The concept of SLNs was ﬁrst described in 1960 by Gould et al.11
The main goal of this procedure is to reduce the extent of surgicalDetection methods Pathological assessment
Preoperative Intraoperative
Lymphoscintigraphy Endoscope gamma probe
Direct visualization
H/E and IHC
Lymphoscintigraphy Endoscope gamma probe
Direct visualization
H/E and IHC
d Direct visualization NA
Lymphoscintigraphy Endoscope gamma probe
Direct visualization
H/E and IHC
Lymphoscintigraphy Endoscope gamma probe
Direct visualization
H/E and IHC
Lymphoscintigraphy Endoscope gamma probe
Direct visualization
H/E and IHC
Lymphoscintigraphy Endoscope gamma probe
Direct visualization
H/E and IHC
Lymphoscintigraphy Endoscope gamma probe
Direct visualization
H/E and IHC
Lymphoscintigraphy Endoscope gamma probe
Direct visualization
H/E and IHC
d eosin, IHC ¼ immunohistochemistry; NA ¼ not available; PB ¼ Patent blue dye;
Table 2
Diagnostic performance included.
Authors No. of patients
with detected SLNs
No. of SLNs
removed
Mean no. of
SLNs removed
Detection rate (%) Bilateral DR Sensitivity Negative predictive
value
Pelosi et al16 15/16 24 1.6 94 56.5 100 0
Gargiulo et al18 11/11 60 NA 100 35.2 100 100
Holub et al17 21/25 53 2.1 84 81 100 100
Barranger et al28 16/17 42 2.6 94 58.8 100 0
Delpech et al29 19/23 47 2.5 82.6 47.8 NA 10.5
Ballaster et al20 33/38 93 2.5 94 39.4 84 97
Perrone et al22 20/23
10/17
27
14
Mean: 20
2.6 Cervical (69.6)
Hysteroscopy (64.7)
Total: 67.5
37.5
27.3
Total: 33.3
87
58.8
Total: 75
0
Barranger et al21 27/33 71 2.5 81.8 54.5 NA 0
Ballester et al12 111/125 NA 3.0 89 69 84 97
NA ¼ not available; SLN ¼ sentinel lymph node.
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and improves quality of life. The technique is based upon the
concept that tumor cells migrating from a primary tumor will
metastasize to one or a few lymph nodes before affecting other
lymph nodes. If the histology of SLNs is negative, there is no further
metastasis, thus avoiding further surgical intervention. The use of
tracers such as blue dye and radiolabeled colloid around the area of
the tumor allows identiﬁcation of an SLN in themajority of patients.
The status of SLNs can then predict accurately the status of the
other regional lymph nodes.
SLNs for EC are still under investigation. Several studies have
addressed the issue and have provided new data that suggest that
this will be a valid approach, and perhaps a trade-off between no
lymphadenectomy versus systematic lymphadenectomy in patients
with low- and intermediate-risk EC.12,13 The other concept of SLNs in
EC is to avoid complete systemic pelvic and para-aortic lymphade-
nectomy in early stage EC, because 80% of patients with Stage I
diseasewere found to be negative for lymph node involvement. The
revised 2009 FIGO staging system for EC advocates that gyneco-
logical oncologists should perform both pelvic and para-aortic
lymphadenectomy for accurate staging.6 These are important for
theprognosis of disease and subsequent treatmentof thepatients. In
addition, with the recent controversies in the a randomised trial of
lymphadenectomy and of adjuvant external beam radiotherapy in
the treatment of endometrial cancer (ASTEC) and survival effect of
para-aortic lymphadenectomy (SEPAL) studies regarding the role of
lymphadenectomy in early stage EC, the SLN concept is more
pertinent thanever.14,15Reducing theunnecessarymorbidity related
to lymphadenectomy while detecting the cases in which complete
surgical staging is required would be a major breakthrough.
The uterus is a complex structure in which the lymphatic
drainage varies. The techniques and sites of tracer injection are the
major concern for SLN mapping in EC. Pericervical injection is the
most often implemented for identiﬁcation of SLNs in EC. TheTable 3
Location of SLNs in endometrial cancer.
Authors Iliac groups (%)
External iliac Internal iliac Interil
Pelosi et al16 100 (all detected in iliac group)
Gargiulo et al18 100 (all detected in iliac group)
Holub et al17 34 13.2
Barranger et al28 50 (medial EI) 52.4 31
Delpech et al29 57.4 (medial EI)
Ballaster et al20 75 (lateral EI) 16.2
Perrone et al22 Cervical 93.8 (iliac group)
Hysteroscopy 90.9 (iliac group)
Barranger et al21 66.7 2.8 19.7
Ballester et al12 NA
EI ¼ external iliac; NA ¼ not available.advantages of pericervical injection for SLN mapping are its feasi-
bility, reproducibility, and low degree of invasiveness compared to
other methods. However, it does not reﬂect lymphatic drainage of
Stage I disease and it has more potential in Stage II disease.
Although cervical injection can overlook some direct lymphatic
drainage to the para-aortic area, the analyzed studies found that
cervical dual labeling is associated with the highest rate of peri-
operative SLN detection; ranging in the pooled data from 69% to
100%.13,16e22 To avoid missing promontory or para-aortic SLNs,
fundal myometrial injection and hysteroscopy-guided injection can
be advocated. Perrone et al showed that the SLN detection ratewith
the hysteroscopy-guided injection technique was only 64.7%, but
there was signiﬁcant isolated para-aortic SLN detection compared
with that with pericervical injection (18.2% vs. 0%, p < 0.05).22 The
issues of hysteroscopy-guided injection are: it is a more compli-
cated technique than direct cervical or uterine corpus injection, and
there is a risk of disseminating malignant cells through the tubes.
Hysteroscopic visualization of the endometrial cavity can be ach-
ieved with a pressure of 40 mmHg, which is lower than the
70mmHg pressure needed for tubal spillage to occur, thus reducing
the risk of malignant cell dissemination into the peritoneal cavity.23
A recent meta-analysis of 26 studies revealed that the detection
rate decreased when pericervical injection was not used, and the
authors suggested that the “subserosal injection only” technique
should not be used because it may decrease the sensitivity of SLN
biopsy.13
The uterus is located at middle of pelvis and should have
bilateral lymphatic drainage, thus it is important to discuss the
bilateral detection rate of SLNs. However, the studies so far have not
conﬁrmed this hypothesis and the percentage of bilateralism varied
between 33.3% and 81% (Table 2). The reasons for which a median
organ can in some cases only drain to one side still remain to be
clariﬁed.22 The most frequent site of nodal metastasis detection in
EC when cervical injections are used is the pelvic area, especially inCommon iliac (%) Bifurcation
of aorta (%)
Para-aortic (%)
iac Obturator
e 0 0 0
e 0 0 0
52.8 13.2 0 0
9 5 0 2.5
e e 1 0
e 7.5 1 0
0.6 0 0 0
0.6 0 0 18.2
5.6 2.8 1.4 0
5
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in the common iliac region and bifurcation of the aorta. When
hysteroscopy-guided injection is advocated, there is an 18.3%
detection rate of SLNs in the para-aortic area.
The other main goal of our review was to underline the ad-
vantages of laparoscopy surgery in EC staging. Use of a minimally
invasive approach in the staging and treatment of EC decreases
perioperative morbidity and appears to result in comparable
treatment effectiveness when compared with laparotomy in early
stage EC.24 A meta-analysis of four randomized trials compared
women with endometrial carcinoma who underwent complete
surgical staging with a minimally invasive approach versus con-
ventional laparotomy. The authors concluded that although the
operative time was longer in the laparoscopy group, there were
some advantages when compared with laparotomy. In patients
treated with laparoscopy, there was a decreased incidence of
perioperative complications, namely, decreased blood loss. The
authors also reported that the group that underwent laparoscopic
staging had shorter hospital stays and faster return to normal ac-
tivity. Of paramount importance in this meta-analysis was the fact
that there was no signiﬁcant difference between the numbers of
lymph nodes yielded in both groups. Regarding cancer survival,
pooled data from this study were limited because only two trials
reported long-term follow-up, at a median of 44 and 79 months.
However there were no signiﬁcant differences between surgical
groups in overall disease-free or cancer-related survival.25
A subsequent randomized study, conducted by the Gynecologic
Oncology Group, assigned >2600 patients with EC to laparoscopy
or laparotomy. All patients underwent hysterectomy and surgical
staging including pelvic and para-aortic node dissection. The re-
sults showed that the minimally invasive approach was feasible
and safe and the complication rates were similar regardless of the
surgical approach. Longer follow-up is ongoing to determine
whether there are differences in recurrence and survival between
the laparotomy and laparoscopy groups.26
A recent study by Mais et al compared the SLN detection rate
obtained through the laparoscopic or laparotomic approach after
pericervical injection of vital dye in patients with early stage EC.
They found that a higher SLN detection ratewas obtainable through
laparoscopy as compared with laparotomy (82% vs. 41%, p ¼ 0.008).
The different detection rates observed between these routes might
depend on the different time elapsing between injection of the blue
dye into the cervix and the surgical SLN assessment in the pelvic
basinwhere the time interval for laparoscopy is always shorter than
for laparotomy.27
Several reviews have analyzed the feasibility and clinical accu-
racy of SLNs in relation to the use of single or dual tracers, methods
of detection, and site of tracer injection, but none of the reviews
investigated the laparoscopic approach to SLN detection in EC. The
advantage of laparoscopic surgery combined with the concept of
SLNs helps to reduce surgical morbidity, especially in women with
EC, who often have comorbidity such as obesity, hypertension, or
diabetes. SLN detection improves the diagnostic accuracy of dis-
ease, which consequently improves disease treatment and then
prognosis. The future development of SLNs includes standardized
methods of laparoscopic detection and pathological examination.
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